Clinical Trial Update: BÜHLMANN fCAL™ ELISA - Aid in Differentiation of IBD From IBS

View source ↗

Summary

A completed clinical trial evaluates the Bühlmann fCAL ELISA as a diagnostic aid to differentiate inflammatory bowel disease from irritable bowel syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Bowel Disease
• Irritable Bowel Syndrome

Snippet

Sponsor: Bühlmann Laboratories AG | Conditions: Inflammatory Bowel Disease, Irritable Bowel Syndrome | Status: COMPLETED